Gliatech and Chugai sign licensing agreement:
This article was originally published in Clinica
Chugai Pharmaceutical is to market Gliatech's Adcon-L and Adcon-T/N anti-adhesion barrier gels in Japan under an exclusive licence agreement announced by the two companies on January 13th. Chugai will fund and conduct all clinical trials and regulatory filings required to obtain marketing approval for the products in Japan. Adcon-L and Adcon-T/N are the first in a line of products being developed by Gliatech (US) for the inhibition of post-surgical scarring and adhesions. Both products are already on the market in Europe, and are in clinical trials in the US.